10 Stocks Stealing Today’s Spotlight; 5 on All-Time Highs

6. Hims & Hers Health, Inc. (NYSE:HIMS)

Hims & Hers soared by 16.18 percent on Wednesday to end at $62.76 apiece as investors cheered the company’s optimism that it would surpass its $1 billion revenue target from women’s health alone in 2026.

This followed the official launch of new menopause and perimenopause treatment plans tailored to women’s health history and personal preferences.

For eligible customers, personalized menopause and perimenopause treatment plans may include prescription medications in the form of pills, patches, or creams, while treatments for eligible customers may include estradiol—a hormone naturally made in the body—to help alleviate symptoms of menopause like hot flashes and night sweats, and progesterone, which helps protect the uterine lining and improve sleep quality.

With Hims & Hers Health, Inc. (NYSE:HIMS) serving more than half a million subscribers, the new product is expected to support its Hers revenue target in 2026.

“Transforming the healthcare experience for women starts with increasing access to providers who are trained specifically in caring for women at every life stage. As one of the largest digital health platforms, we can help change the way women experience healthcare and thrive,” said Hers Chief Medical Officer Jessica Shepherd.